SciSparc: NeuroThera Labs Granted U.S. Patent for Cannabinoid Technology to Overcome ...

SciSparc: NeuroThera Labs Granted U.S. Patent for Cannabinoid Technology to Overcome ...

NeuroThera’s Proprietary Cannabinoid-Enhanced Platform Targets Antibiotic Resistance Using Approved Antimicrobials

Neurothera cannabinoid tech disarms antibiotic resistance

Neurothera Labs (TSXV:NTLX) has been granted a US patent for combining antimicrobials and cannabinoids designed to fortify antibiotics against resistant bacterial strains Neurothera, a majority-owned subsidiary of SciSparc (NASDAQ:SPRC), is a clinical-stage pharmaceutical company developing therapeutics for central nervous system disorders and other underserved health conditions Neurothera stock last traded at C$0.20 Clinical-stage biotech compa…

Neurothera Labs Granted U.S. Patent for Cannabinoid Technology to Overcome Antimicrobial Resistance such as MRSA

Open the article to view the coverage from thenewswire.com